# Extended follow-up of randomized participants in the INSIGHT START trial

> **NIH NIH U01** · UNIVERSITY OF MINNESOTA · 2020 · $4,517,512

## Abstract

PROJECT SUMMARY
INSIGHT is serving as lead clinical trials network for the development of a master protocol for
trials of therapeutic neutralizing monoclonal antibodies (nMAbs) for patients hospitalized with
COVID-19. Two NHLBI networks, PETAL and CTSN, the ACTG and Veterans Administration
are collaborating with us on the development of the master protocol and will enroll patients in
the trial we lead. The master protocol has been reviewed by CSRC and, following that review,
the protocol will be submitted to the FDA.
There are many nMAbs to study and we anticipate rolling different treatments into this trial over
the next 2 years. We anticipate the first nMAb to study will be available to begin the first trial in
July 2020. This grant supplement will be used to support the INSIGHT SDMC, 4 INSIGHT
ICCs. It will also support subcontracts with our central specimen repository (ABML) and a drug
distribution company (PCI Pharma).

## Key facts

- **NIH application ID:** 10198271
- **Project number:** 3U01AI136780-02S2
- **Recipient organization:** UNIVERSITY OF MINNESOTA
- **Principal Investigator:** James Dennis Neaton
- **Activity code:** U01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2020
- **Award amount:** $4,517,512
- **Award type:** 3
- **Project period:** 2020-07-15 → 2023-04-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10198271

## Citation

> US National Institutes of Health, RePORTER application 10198271, Extended follow-up of randomized participants in the INSIGHT START trial (3U01AI136780-02S2). Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/grant/nih/10198271. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*